What is the recommended management of severe preeclampsia (blood pressure ≥160/110 mm Hg) in pregnancy, including admission, monitoring, antihypertensive therapy, magnesium sulfate seizure prophylaxis, laboratory evaluation, corticosteroid use, and timing of delivery?

Management of Severe Preeclampsia

Women with severe preeclampsia (BP ≥160/110 mm Hg) require immediate hospitalization in a monitored setting with urgent antihypertensive therapy using oral nifedipine or IV labetalol/hydralazine, magnesium sulfate for seizure prophylaxis when proteinuria or neurological symptoms are present, and delivery at 37 weeks or earlier if severe features develop. 1

Immediate Admission and Monitoring

All women with severe preeclampsia must be hospitalized for close monitoring in obstetric centers with adequate maternal and neonatal intensive care resources 2. The high rate and unpredictable nature of complications make outpatient management inappropriate at this severity level.

Maternal monitoring includes:

• Blood pressure checks at least every 4-6 hours 1
• Clinical assessment for clonus and neurological symptoms (headache, visual scotomata) 1
• Laboratory testing at minimum twice weekly for: hemoglobin, platelet count, liver transaminases (AST/ALT), creatinine, and uric acid 1
• Fluid balance monitoring, limiting total intake to 60-80 mL/hour to prevent pulmonary edema 1

Fetal monitoring includes:

• Initial ultrasound assessment of fetal biometry, amniotic fluid, and umbilical artery Doppler 1
• Serial surveillance every 2 weeks if initial assessment normal 1
• More frequent monitoring if fetal growth restriction present 1

Urgent Antihypertensive Therapy

Blood pressure ≥160/110 mm Hg lasting >15 minutes warrants immediate drug treatment to prevent maternal stroke and hemorrhagic complications 2. This threshold represents a medical emergency regardless of symptoms.

First-line agents for acute severe hypertension:

• Oral nifedipine: 10 mg, repeat every 20 minutes to maximum 30 mg 3
• IV labetalol: 20 mg bolus, then 40 mg after 10 minutes, then 80 mg every 10 minutes for 2 additional doses (maximum 220 mg) 3
• IV hydralazine: 5 mg bolus, then 10 mg every 20-30 minutes to maximum 25 mg 3

Oral labetalol may be used if these are unavailable 1. Methyldopa should NOT be used for urgent BP reduction 2.

Maintenance Antihypertensive Therapy

For persistent non-severe hypertension (≥140/90 mm Hg), treatment should target diastolic BP of 85 mm Hg and systolic BP 110-140 mm Hg 1. This approach reduces likelihood of severe hypertension and complications. Acceptable maintenance agents include oral methyldopa, labetalol, oxprenolol, and nifedipine 1.

Reduce or cease antihypertensives if diastolic BP falls <80 mm Hg 1.

Magnesium Sulfate for Seizure Prophylaxis

Women with preeclampsia who have proteinuria AND severe hypertension, OR hypertension with neurological signs/symptoms, should receive magnesium sulfate 1. This is critical for preventing eclampsia, which magnesium sulfate reduces by approximately 50% 1.

Dosing regimen (per FDA label and guidelines):

• Loading dose: 4-5 g IV over 3-4 minutes (diluted to 10-20% concentration), OR 4 g IV plus 10 g IM (5 g in each buttock) 4
• Maintenance: 1-2 g/hour continuous IV infusion, OR 4-5 g IM every 4 hours 4
• Duration: Continue until delivery and for 24 hours postpartum 1

Critical safety monitoring:

• Check patellar reflexes before each dose; hold if absent 4
• Monitor respiratory rate (should be ≥16 breaths/min) 4
• Target serum magnesium level: 3-6 mg/100 mL (2.5-5 mEq/L) 4
• Have IV calcium gluconate immediately available as antidote 4

Important caveat: Do NOT give magnesium sulfate concomitantly with calcium channel blockers due to risk of severe hypotension 2. Continuous use beyond 5-7 days can cause fetal abnormalities 4.

In low-resource settings, all women with preeclampsia should receive magnesium sulfate using simplified regimen: 4 g IV or 10 g IM loading dose, then 5 g IM every 4 hours 1.

Laboratory Evaluation

Initial workup:

• Complete blood count (hemoglobin, platelets)
• Comprehensive metabolic panel (creatinine, liver enzymes)
• Uric acid
• Urinalysis with protein quantification (protein/creatinine ratio ≥30 mg/mmol is abnormal) 1

Ongoing monitoring: Repeat labs at least twice weekly and immediately with any clinical status change 1. More frequent testing indicated if values are abnormal or trending worse.

Corticosteroid Administration

Antenatal corticosteroids are recommended for women with severe preeclampsia between 24-34 weeks gestation to promote fetal lung maturity 1, 5. Administer without delaying delivery to complete the course if immediate delivery is indicated 6.

Standard regimen: betamethasone 12 mg IM every 24 hours for 2 doses, or dexamethasone 6 mg IM every 12 hours for 4 doses.

Timing of Delivery

Delivery is indicated at 37 weeks + 0 days gestation for all women with preeclampsia 1. This is the definitive treatment.

Immediate delivery is required at ANY gestational age if:

• Repeated severe hypertension despite 3 classes of antihypertensive agents 1
• Progressive thrombocytopenia 1
• Progressively abnormal liver or renal function tests 1
• Pulmonary edema 1
• Severe intractable headache, repeated visual scotomata, or convulsions 1
• Non-reassuring fetal status 1

Between 34-37 weeks: Expectant conservative management may be considered if condition is stable, with close monitoring 1

Between 24-34 weeks: Expectant management in highly selected patients only, with intensive monitoring 5. Delivery recommended after 34 weeks with severe features 2.

Before 24 weeks: Termination of pregnancy should be discussed given extremely poor prognosis 7.

Neither serum uric acid level nor degree of proteinuria should be used as isolated indications for delivery 1.

Common Pitfalls to Avoid

• Do not delay treatment waiting for BP to be "severe enough"—treat persistently elevated BP ≥140/90 mm Hg to prevent progression 1
• Do not use NSAIDs for postpartum pain in preeclamptic women, especially with renal impairment; use alternative analgesia 1
• Do not perform plasma volume expansion routinely—these women have capillary leak and are at risk for pulmonary edema 1
• Do not give magnesium sulfate with calcium channel blockers simultaneously due to synergistic hypotensive effects 2
• Do not continue magnesium sulfate beyond 5-7 days due to risk of fetal skeletal abnormalities 4
• Do not discharge early postpartum—10% of maternal deaths from hypertensive disorders occur in the postpartum period, with up to 44% in first 6 days 2, 6

Postpartum Management

Continue close monitoring for at least 3 days postpartum with BP checks every 4-6 hours 1. Preeclampsia can develop de novo postpartum or worsen after delivery. Continue magnesium sulfate for 24 hours postpartum in most cases 1. Taper antihypertensives slowly only after days 3-6 unless BP becomes low (<110/70 mm Hg) 1.